Shire Human Genetic Therapies Inc. has discovered new plasma kallikrein (KLKB1) inhibitors reported to be useful for the treatment of hereditary angioedema and diabetic macular edema.
Researchers from the International Centre for Genetic Engineering and Biotechnology and colleagues have worked on the systematic identification of cellular proteins that can exert cardioprotective activity after a myocardial infarction (MI).
Zhejiang University has disclosed transient receptor potential cation channel subfamily M member 2 (TRPM2) antagonists reported to be useful for the treatment of stroke and ischemia-reperfusion injury, among others.
Researchers from the University of California and affiliated organizations have published data from a study that focused on screening of factors involved in hepatic low-density lipoprotein receptor (LDLR) regulation, with the aim of identifying potential new therapeutic targets in cardiovascular disease.
Ambulero Inc., a spinout from the University of Miami Miller School of Medicine, has received a positive response from a type B pre-IND meeting with the FDA on the development of AMB-301 as a treatment for the vascular disease Buerger's disease.
The coagulation factor XI (FXI) from the liver acts as an endocrine molecule in the heart, protecting it from heart failure. Scientists at the University of California, Los Angeles (UCLA) found that this communication between the two organs is mediated by the interaction between FXI and a heart protein. This interaction activated genes in cardiomyocytes that reduced inflammation, fibrosis and diastolic dysfunction, protecting the heart from a heart attack. That FXI participates in preventing heart failure suggests the possibility of using it as a therapeutic target.
The University of Antwerp has identified new quinazolin-4-one and thieno[2,3-d]pyrimidin-4-one HER4 (ERBB4) inhibitors reported to be useful for the treatment of heart failure, cancer, fibrosis, and metabolic and inflammatory disorders.
Aqualung Therapeutics Corp. has been awarded two 3-year National Institutes of Health (NIH) Fast Track awards to support development of ALT-100 (enamptcumab), a humanized monoclonal antibody therapy for the chronic indications of pulmonary arterial hypertension (PAH) and inflammatory bowel disease (IBD).
Synthetic cells (SCs) armed with recombinant growth factors could contribute to tissue regeneration and healing by promoting angiogenesis. This technology opens the door to its application in other therapies such as transplants that require the remodeling or formation of new blood vessels. In addition, they mark the way to produce intracorporeal biological drugs or the inhibition of the angiogenesis process itself when it comes to blocking the irrigation of a tumor.
RSS
